Vasculox Archive: A Research Legacy in CD47 Biology

This archive preserves the scientific record of Vasculox, Inc., a former biomedical research organization that investigated the role of CD47 and thrombospondin-1 in vascular biology. The content below is drawn from previously published materials and is presented for historical and educational purposes only. Vasculox, Inc. is no longer operating, and this site is not affiliated with any current entity.

Research Focus: CD47 and Nitric Oxide Signaling

Vasculox, Inc. was a biomedical research organization that focused on the role of the cell-surface protein CD47 and its ligand thrombospondin-1 (TSP1) in vascular health and disease. The company's published work centered on how the TSP1-CD47 system inhibits nitric oxide (NO) signaling, a critical pathway for blood vessel function. By understanding this interaction, Vasculox aimed to identify new therapeutic targets for conditions involving vascular injury and inflammation.

The archived research highlights that CD47, when activated by TSP1, disrupts the normal association between CD47 and caveolin-1 (Cav-1) in endothelial cells. This disruption promotes the production of superoxide, a reactive oxygen species, and reduces NO bioavailability. These molecular events were shown to contribute to vascular dysfunction in experimental models, providing a mechanistic link between CD47 activation and disease progression.

Key Publication: CD47 in Pulmonary Arterial Hypertension

One of the central studies preserved in this archive is the 2012 publication by Bauer et al. in Cardiovascular Research, titled 'Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1.' The study investigated the role of activated CD47 in pulmonary arterial hypertension (PAH), a progressive lung disease characterized by pulmonary vasoconstriction and vascular remodeling, leading to increased pulmonary vascular resistance and right heart failure.

The researchers reported high-level expression of TSP1 and CD47 in the lungs of human subjects with PAH, as well as increased expression in experimental models. They found that in pulmonary endothelial cells, CD47 constitutively associates with Cav-1, but under hypoxic conditions, activation of CD47 by TSP1 disrupts this interaction, promoting eNOS-dependent superoxide production and oxidative stress. Importantly, hypoxic TSP1-null mice developed less right ventricular pressure and hypertrophy, and therapeutic blockade of CD47 activation in hypoxic cells protected animals from developing PAH. These findings suggested that CD47 activation is a key driver of PAH pathology.

Additional Research: CD47 Blockade in Ischemia-Reperfusion Injury

Vasculox also contributed to research on ischemia-reperfusion injury (IRI), a condition that contributes to delayed graft function and inflammation in organ transplantation. A 2014 study by Lin et al., published in Transplantation, examined the effects of CD47 blockade in a rat kidney transplant model. The study found that blocking CD47 reduced ischemia-reperfusion injury and improved outcomes, likely by preserving nitric oxide signaling and reducing inflammation.

Earlier, in 2013, Vasculox presented a poster at the American Transplant Congress titled 'Blocking CD47 reduces ischemia reperfusion injury and improves kidney transplantation outcomes.' The abstract highlighted that many components of IRI are ameliorated by nitric oxide signaling, and that the endogenous TSP1-CD47 system inhibits this pathway. These findings underscored the potential of CD47 as a therapeutic target in transplantation and vascular injury.

Scientific Advisory Board and Collaborations

The archived website describes Vasculox's collaboration with a scientific advisory board composed of experts in vascular biology, drug development, and transplantation. The board was chaired by Jeffrey S. Isenberg, MD, MPH, a vascular surgery expert and cofounder of Vasculox, who was then an Associate Professor of Medicine at the University of Pittsburgh School of Medicine. Other members included Charles T. Esmon, Ph.D., an expert in hemostasis and endothelial function; Keith Hruska, MD, an expert on organ transplantation; and William C. Chapman, MD, a transplant surgeon.

Additional board members included Garland R. Marshall, Ph.D., an expert in molecular modeling and rational drug design; Robert P. Mecham, Ph.D., an expert in vascular biology and extracellular matrix; and Ronald C. Merrell, MD, FACS, an expert in general surgery and tissue ischemia. These collaborations reflected Vasculox's commitment to advancing its research through partnerships with leading scientists and clinicians.

Legacy and Archival Purpose

This archive serves as a historical record of Vasculox, Inc.'s scientific contributions. The research preserved here has advanced the understanding of CD47 biology and its role in vascular disease, particularly in the context of nitric oxide signaling and oxidative stress. While Vasculox, Inc. is no longer an active entity, its published findings continue to inform the broader scientific community.